Truist Financial Cuts Pediatrix Medical Group (NYSE:MD) Price Target to $16.00

Pediatrix Medical Group (NYSE:MD) had its price objective cut by Truist Financial from $18.00 to $16.00 in a research note released on Friday,Benzinga reports. They currently have a hold rating on the stock.

MD has been the topic of several other reports. Macquarie began coverage on Pediatrix Medical Group in a research note on Monday, December 16th. They set an “outperform” rating and a $18.00 price objective on the stock. UBS Group raised their price target on shares of Pediatrix Medical Group from $16.50 to $18.50 and gave the company a “neutral” rating in a research report on Friday, February 21st. Finally, StockNews.com raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Wednesday, January 22nd. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Pediatrix Medical Group presently has an average rating of “Hold” and an average target price of $16.75.

Pediatrix Medical Group Stock Down 1.5 %

Pediatrix Medical Group stock opened at $13.35 on Friday. The company has a current ratio of 1.60, a quick ratio of 1.42 and a debt-to-equity ratio of 0.81. The firm’s fifty day moving average price is $14.33 and its two-hundred day moving average price is $13.93. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -11.13, a price-to-earnings-growth ratio of 1.74 and a beta of 1.32. Pediatrix Medical Group has a 1-year low of $6.62 and a 1-year high of $17.67.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings results on Thursday, February 20th. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.12. The business had revenue of $502.36 million for the quarter, compared to analysts’ expectations of $486.22 million. Pediatrix Medical Group had a negative net margin of 4.92% and a positive return on equity of 15.47%. On average, equities research analysts predict that Pediatrix Medical Group will post 1.38 earnings per share for the current fiscal year.

Institutional Trading of Pediatrix Medical Group

A number of large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its position in shares of Pediatrix Medical Group by 4,530.0% during the 1st quarter. GAMMA Investing LLC now owns 37,225 shares of the company’s stock valued at $539,000 after acquiring an additional 36,421 shares during the period. California State Teachers Retirement System grew its holdings in Pediatrix Medical Group by 0.9% during the fourth quarter. California State Teachers Retirement System now owns 80,327 shares of the company’s stock valued at $1,054,000 after purchasing an additional 752 shares during the period. Mackenzie Financial Corp bought a new position in Pediatrix Medical Group during the fourth quarter valued at $276,000. PharVision Advisers LLC purchased a new stake in Pediatrix Medical Group in the fourth quarter worth $245,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Pediatrix Medical Group by 7.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 256,335 shares of the company’s stock valued at $3,363,000 after buying an additional 18,627 shares during the period. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.